[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100611568":3},{"organization":4,"outcomesModule":7,"designInfo":23,"detailedDescription":22,"studyPopulation":22,"armGroups":29,"interventions":42,"overallOfficials":48,"centralContacts":53,"locations":59,"responsibleParty":76,"collaborators":22,"id":78,"slug":22,"hasResults":79,"nctId":80,"briefTitle":81,"officialTitle":82,"acronym":22,"eligibilityCriteria":83,"healthyVolunteers":79,"sex":84,"minAge":85,"maxAge":22,"enrollmentInfo":86,"targetDuration":22,"studyType":89,"phases":90,"briefSummary":92,"conditions":93,"keywords":22,"overallStatus":95,"whyStopped":22,"lastUpdateSubmitDate":96,"lastUpdatePostDateStruct":97,"startDateStruct":100,"completionDateStruct":102,"leadSponsor":104,"locationsCount":105},{"fullName":5,"class":6},"Jemincare","INDUSTRY",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":22},[9],{"measure":10,"description":11,"timeFrame":12},"PFS","Progression-Free Survival","1 year",[14,18],{"measure":15,"description":16,"timeFrame":17},"OS","Overall Survival","3 years",{"measure":19,"description":20,"timeFrame":21},"AE","Adverse Event","from first dose to 28 days after the last dose",null,{"allocation":24,"interventionModel":25,"interventionModelDescription":22,"primaryPurpose":26,"observationalModel":22,"timePerspective":22,"maskingInfo":27},"RANDOMIZED","PARALLEL","TREATMENT",{"masking":28,"maskingDescription":22,"whoMasked":22},"NONE",[30,36],{"label":31,"type":32,"description":33,"interventionNames":34},"JMKX001899","EXPERIMENTAL","Orally, once daily",[35],"Drug: JMKX001899",{"label":37,"type":38,"description":39,"interventionNames":40},"Docetaxel","ACTIVE_COMPARATOR","By IV infusion every 21 days",[41],"Drug: Docetaxel",[43,46],{"type":44,"name":31,"description":33,"armGroupLabels":45,"otherNames":22},"DRUG",[31],{"type":44,"name":37,"description":39,"armGroupLabels":47,"otherNames":22},[37],[49],{"name":50,"affiliation":51,"role":52},"Jie Wang, Doctor","Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, China","PRINCIPAL_INVESTIGATOR",[54],{"name":55,"role":56,"phone":57,"phoneExt":22,"email":58},"Fawei Wu","CONTACT","+86 15720614080","wufawei@jeyoupharma.com",[60],{"facility":51,"status":22,"city":61,"state":62,"zip":63,"country":64,"countryCode":65,"cosmosGeoPoint":66,"geoPoint":71,"contacts":72},"Beijing","Beijing Municipality","100021","China","CN",{"type":67,"coordinates":68},"Point",[69,70],116.39723,39.9075,{"lat":70,"lon":69},[73],{"name":50,"role":56,"phone":74,"phoneExt":22,"email":75},"+86 13910704669","zlhuxi@163.com",{"type":77,"investigatorFullName":22,"investigatorTitle":22,"investigatorAffiliation":22,"oldNameTitle":22,"oldOrganization":22},"SPONSOR","100611568",false,"NCT07242274","Phase 3 Trial of JMKX001899 Versus Docetaxel in Previously Treated Advanced or Metastatic KRAS G12C-Mutant NSCLC","A Multicenter, Randomized, Open-Label, Phase 3 Study Evaluating the Efficacy and Safety of JMKX001899 Versus Docetaxel in Previously Treated Patients With KRAS G12C-Mutant Advanced or Metastatic Non-Small Cell Lung Cancer","Inclusion Criteria:\n\n1. Age ≥ 18 years.\n2. Histologically or cytologically confirmed NSCLC.\n3. Failure of at least one prior line of therapy for locally advanced\u002Fmetastatic disease, that included a platinum-based chemotherapy and a PD-1\u002FPD-L1 inhibitor.\n4. At least one measurable lesion as defined by RECIST version 1.1.\n\nExclusion Criteria:\n\n1. Known concomitant presence of other oncogenic driver mutations or rearrangements with established targeted therapies .\n2. Previous treatment with any KRAS G12C-targeted agent.\n3. Prior docetaxel therapy in the locally advanced\u002Fmetastatic setting.","ALL","18 Years",{"count":87,"type":88},472,"ESTIMATED","INTERVENTIONAL",[91],"PHASE3","This is a multicenter, randomized, open-label, phase 3 clinical trial designed to evaluate the efficacy and safety of JMKX001899 compared to docetaxel in patients with previously treated, KRAS G12C-mutant advanced or metastatic non-small cell lung cancer (NSCLC).\n\nKRAS G12C mutation is present in a subset of NSCLC patients. While docetaxel is a standard chemotherapy option, JMKX001899 is an investigational, targeted therapy designed to selectively inhibit the KRAS G12C mutation. This trial aims to determine whether JMKX001899 offers a superior clinical benefit compared to standard chemotherapy.",[94],"NSCLC (Non-small Cell Lung Cancer)","NOT_YET_RECRUITING","2025-11-17",{"date":98,"type":99},"2025-11-21","ACTUAL",{"date":101,"type":88},"2025-12-31",{"date":103,"type":88},"2029-12-30",{"name":5,"class":6},1]